zolpidem has been researched along with paroxetine in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Katz, SE | 1 |
| Meyer, C | 1 |
| de Boissezon, X; de Boysson, C; Démonet, JF; Peran, P | 1 |
| Blin, D; Derderian, F; Durand, M; Gonthier, YT; Mongenot, F | 1 |
| Chen, ZQ; Ji, JL; Liu, WJ; Mei, QY; Pan, JY; Tao, M; Wang, YP; Wei, J; Zhang, N; Zhao, ZX; Zheng, AL | 1 |
| Chaslerie, A; Feuillet, F; Hardouin, JB; Jolliet, P; Pivette, J; Sébille, V; Victorri-Vigneau, C; Wainstein, L | 1 |
| Liu, Y; Mao, HJ; Song, MF; Tang, GZ; Wang, SD; Xu, XH; Yin, Y; Yu, ZH | 1 |
2 review(s) available for zolpidem and paroxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacotherapy of aphasia: myth or reality?
Topics: Amphetamine; Aphasia; Bromocriptine; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Fluoxetine; GABA Agonists; Humans; Indans; Neuroprotective Agents; Paroxetine; Physostigmine; Piperidines; Piracetam; Pyridines; Selective Serotonin Reuptake Inhibitors; Serotonin; Stroke; Zolpidem | 2007 |
2 trial(s) available for zolpidem and paroxetine
| Article | Year |
|---|---|
[Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study].
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Outcome Assessment, Health Care; Paroxetine; Pyridines; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Zolpidem | 2007 |
Effect and safety of paroxetine combined with zolpidem in treatment of primary insomnia.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Polysomnography; Pyridines; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Wakefulness; Zolpidem | 2017 |
14 other study(ies) available for zolpidem and paroxetine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Possible paroxetine-zolpidem interaction.
Topics: Adolescent; Delirium; Drug Interactions; Female; Humans; Hypnotics and Sedatives; Paroxetine; Pyridines; Zolpidem | 1995 |
New drugs. In the realm of the brain.
Topics: Central Nervous System Agents; Depression; Humans; Hypnotics and Sedatives; Migraine Disorders; Paroxetine; Pyridines; Sleep Initiation and Maintenance Disorders; Sumatriptan; Zolpidem | 1993 |
[Treatment of hydroxychloroquine poisoning with extracorporeal circulation].
Topics: Adult; Antidotes; Bromazepam; Charcoal; Coma; Combined Modality Therapy; Diazepam; Drug Overdose; Epinephrine; Extracorporeal Circulation; Female; Fluid Therapy; Gastric Lavage; Heart Massage; Humans; Hydroxychloroquine; Hypokalemia; Paroxetine; Plasma Substitutes; Potassium; Pyridines; Shock, Cardiogenic; Sodium Channel Blockers; Suicide, Attempted; Vasoconstrictor Agents; Ventricular Fibrillation; Zolpidem | 2007 |
Pharmacoepidemiological characterization of psychotropic drugs consumption using a latent class analysis.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Bromazepam; Databases, Factual; Drug Utilization; France; Humans; Hypnotics and Sedatives; Paroxetine; Pyridines; Risk; Substance-Related Disorders; Zolpidem | 2011 |